Novartis digs deeper into cancer with up to $750 mln Aduro deal

March 30 (Reuters) - Swiss drugmaker Novartis is digging deeper into the world of cancer immunotherapy - one of the hottest areas of drug research - through a tie-up with California-based Aduro Biotech worth up to $750 million.